Avecho Biotechnology Limited (AVE) AI Stock Analysis

• Market Cap: AU$36.73M
• Dividend Yield: N/A
• Average Volume (3M): N/A
• Price to Earnings (P/E): ―
• Beta (1Y): 1.87
• Revenue Growth: 306.88%
• EPS Growth: N/A
• Country: AU
• Employees: 29
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 0.00
• Shares Outstanding: 3,673,463,600
• 10 Day Avg. Volume: N/A
• 30 Day Avg. Volume: N/A
• PEG Ratio: -0.17
• Price to Book (P/B): 18.85
• Price to Sales (P/S): 23.75
• P/FCF Ratio: 26.65
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 48 Neutral
• Price Target: AU$0.01 ▲(0.00% Upside)
• Action: Reiterated Date: 03/02/26
• Date: Action: Reiterated 03/02/26

The score is primarily constrained by continued sizable losses and shrinking equity despite improving revenue and a 2025 turnaround to positive cash flow. High volatility (beta) and a negative P/E further temper the outlook, while missing technical and dividend data limit additional support.

Positive Factors

Improved cash generation

Avecho’s shift to positive operating and free cash flow in 2025 indicates the business has started to generate internal funding for operations and development. This reduces near-term external funding dependence, supports execution of partnerships or product launches, and lengthens runway if sustained.

Low leverage / manageable debt

Very low debt provides financial flexibility, lowering default risk and interest burdens. This balance sheet posture enables Avecho to invest in R&D or partner deals without heavy fixed financing costs, preserving ability to pursue licensing opportunities and weather development cycles.

Proprietary TPM platform and licensing model

Avecho’s proprietary Tocopheryl Phosphate Mixture (TPM) and a licensing/partner model create a scalable route to revenue without bearing full commercial cost. Licensing can produce upfront, milestone and royalty streams, leveraging partner resources and accelerating market reach across pharma and consumer health.

Negative Factors

Persistent operating and net losses

Sustained multi‑year operating losses erode capital and indicate core profitability challenges. Unless offset by recurring licensing income or meaningful margin improvement, continued losses will impair returns, constrain reinvestment and may force dilutive capital raises that weaken shareholder value.

Declining equity / value erosion

A shrinking equity base reduces the company’s loss-absorption buffer and limits capacity to use leverage for growth. This deterioration limits strategic optionality, weakens negotiating power with partners, and raises the stakes of any further operating setbacks or unexpected cash needs.

Volatile cash flow history

Large year-to-year swings in cash generation make financial planning and multi-year investment decisions harder. Persistent volatility increases the probability of future funding rounds or project delays, and raises execution risk for licensing deals or commercial scale-up that require predictable working capital.

Avecho Biotechnology Limited Business Overview & Revenue Model

Company Description

Avecho Biotechnology Limited, a biotechnology company, develops, produces, and sells products using its patented platform technology, Targeted Penetration Matrix (TPM) drug delivery system for the pharmaceutical, skin care, animal health, and nutrition industries. It offers TPM and Vital ET products for use in drug delivery and cosmetic formulations; and develops TPM/Oxymorphone and TPM/Oxycodone. The company's human health portfolio covers delivery of pharmaceutical products through gels, injectables, and patches. It also provides non-antibiotic feed additive products to enhance feed efficiency and the health of livestock animals. The company has a collaboration with Lambert Initiative at the University of Sydney to conduct a study to examine whether topically applied cannabidiol can provide relief from symptoms of osteoarthritis. It serves customers in Australia, Switzerland, India, and internationally. The company was formerly known as Phosphagenics Limited and changed its name to Avecho Biotechnology Limited in May 2019. Avecho Biotechnology Limited was incorporated in 1992 and is based in Clayton, Australia.

How the Company Makes Money

Avecho Biotechnology Limited generates revenue primarily through the development and licensing of its proprietary TPM technology to pharmaceutical and healthcare companies. The company earns income by entering into licensing agreements with partners who seek to incorporate TPM into their own products to enhance drug delivery and efficacy. Additionally, Avecho may receive milestone payments and royalties based on the commercial success of products developed using its technology. Strategic collaborations and partnerships with industry players are significant contributors to Avecho's earnings, as these alliances help the company to expand its reach and application of its technology across different markets.

Avecho Biotechnology Limited Financial Statement Overview

Summary

Revenue growth accelerated in 2025 and cash flow flipped to positive operating and free cash flow, with low debt levels. However, persistent large operating/net losses and a declining equity base remain the primary financial risk.

Income Statement

Revenue has rebounded with growth accelerating in 2025 (annual revenue up ~12% vs. ~1% in 2024), and gross profit remains positive in the most recent years. However, profitability is a clear कमजोरी: the company continues to post large operating losses and net losses each year (e.g., 2025 net loss ~A$4.4m), with deeply negative margins in the years where margins are provided. Overall, improving top-line momentum is outweighed by persistent and sizable losses.

Balance Sheet

Leverage looks manageable overall: debt is very low in 2025 and was modest relative to equity in 2024 (debt-to-equity ~0.33). That said, equity has declined meaningfully from 2023 to 2025, reflecting ongoing losses, and returns on equity are strongly negative where reported—highlighting value erosion risk if losses persist. Asset base is reasonable, but the key balance-sheet concern is the trajectory of shrinking equity rather than near-term debt pressure.

Cash Flow

Cash generation improved sharply in 2025, with positive operating cash flow (~A$1.1m) and positive free cash flow (~A$1.1m) after multiple years of cash burn (2020–2024 operating cash flow was negative each year). The main weakness is volatility: the swing from materially negative free cash flow in 2024 to positive in 2025 suggests cash flows may be inconsistent and could reverse if funding needs rise or working capital swings.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	1.24M	1.13M	473.55K	1.13M	793.60K
Gross Profit	751.29K	671.93K	-43.80K	793.12K	507.94K
EBITDA	-5.87M	-2.92M	-3.24M	-2.11M	-2.98M
Net Income	-4.42M	-3.12M	-3.44M	-2.34M	-3.42M
Balance Sheet
Total Assets	7.11M	5.00M	7.32M	3.35M	5.25M
Cash, Cash Equivalents and Short-Term Investments	4.66M	2.37M	5.50M	1.47M	3.26M
Total Debt	14.47K	1.08M	175.15K	246.07K	93.91K
Total Liabilities	5.55M	1.73M	941.54K	920.66K	709.36K
Stockholders Equity	1.56M	3.27M	6.38M	2.42M	4.54M
Cash Flow
Free Cash Flow	1.10M	-3.97M	-3.18M	-1.72M	-3.30M
Operating Cash Flow	1.10M	-3.97M	-3.18M	-1.67M	-3.10M
Investing Cash Flow	0.00	-15.73K	0.00	-53.12K	-202.82K
Financing Cash Flow	1.19M	854.59K	7.22M	-78.22K	4.69M

Avecho Biotechnology Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
AVE	48 Neutral	AU$36.73M	-7.14	-143.71%	―	306.88%	―
CHM	45 Neutral	AU$8.84M	―	-469.35%	―	―	46.28%
IMC	44 Neutral	AU$9.15M	-1.50	-49.96%	―	48.63%	25.66%
NOX	43 Neutral	AU$19.97M	-3.46	-157.93%	―	―	-36.89%
1AI	41 Neutral	AU$27.33M	-26.67	-30.33%	―	―	―
MEM	39 Underperform	AU$19.93M	-4.76	-90.15%	―	-93.83%	20.00%

Avecho Biotechnology Limited Corporate Events

Avecho hits key Phase III recruitment milestone in CBD insomnia trial

Avecho Biotechnology has completed recruitment of roughly 210 patients for the interim analysis cohort of its pivotal Phase III trial of a TPM-enhanced cannabidiol capsule for insomnia, with results expected in June 2026. The study is intended to support registration with Australia’s Therapeutic Goods Administration and position the company among the first movers in the country’s emerging over-the-counter CBD insomnia market.

The company estimates the Australian over-the-counter CBD opportunity at more than US$125 million annually within a global insomnia market worth over US$5 billion, and has already licensed Australian rights to Sandoz AG on a deal including an upfront fee, milestones and tiered royalties. Management views the interim analysis as a key inflection point that could materially de-risk the program, strengthen Avecho’s strategic position and bolster ongoing licensing discussions for territories outside Australia.

Avecho’s progress comes amid growing recognition of insomnia as a large, under-served condition with significant economic and public health consequences, particularly in Australia where sleep health has been elevated to a national policy priority. A positive readout from the interim analysis would not only validate the company’s TPM-based CBD technology but could also accelerate commercialisation timelines and draw further interest from global pharmaceutical partners seeking exposure to the sleep and CBD markets.

The most recent analyst rating on (AU:AVE) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on Avecho Biotechnology Limited stock, see the AU:AVE Stock Forecast page.

Avecho Files Updated Corporate Governance Statement and Appendix 4G with ASX

Avecho Biotechnology Limited has lodged its Corporate Governance Statement for the financial year ended 31 December 2025, confirming that the document is current as of 27 February 2026 and has been approved by the board. The statement, accessible via the company’s website, outlines Avecho’s adherence to ASX Corporate Governance Council principles, including board charters, director appointment processes, and executive agreements, reinforcing its compliance and governance framework for investors.

As part of its ASX obligations, Avecho has also submitted a completed Appendix 4G to act as a key for locating its governance disclosures and to verify that it meets Listing Rule 4.10.3 requirements. The filing signals the company’s commitment to formal governance structures, clearly defined board and management responsibilities, and transparent reporting practices that underpin stakeholder confidence.

The most recent analyst rating on (AU:AVE) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on Avecho Biotechnology Limited stock, see the AU:AVE Stock Forecast page.

Avecho Widens Annual Loss Despite Higher Revenue as Development Spending Continues

Avecho Biotechnology Limited has reported a 9.3% increase in revenues from ordinary activities to $1.24 million for the year ended 31 December 2025, while its net tangible assets per ordinary security declined to 0.04 cents from 0.10 cents. The company remains in an investment-heavy development phase, recording a wider after-tax loss of $4.42 million, up 41.5% from the prior year’s $3.12 million, and has again chosen not to declare or pay any dividends, underscoring its focus on funding growth rather than returns to shareholders.

The audited preliminary final report highlights that Avecho did not gain or lose control over any entities, has no associates or joint ventures, and continues to operate without a dividend reinvestment plan. These results align with sector norms for early-stage biotech firms, indicating that shareholders should expect continued prioritisation of research and development and balance sheet preservation over near-term profitability or income distributions.

The most recent analyst rating on (AU:AVE) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on Avecho Biotechnology Limited stock, see the AU:AVE Stock Forecast page.

Avecho nears key Phase III milestone as CEO showcases CBD insomnia program at healthcare forum

Avecho Biotechnology has announced that CEO Dr Paul Gavin will present at the Euroz Hartleys Healthcare Forum, where he will provide an update on the company’s pivotal Phase III clinical trial of its CBD TPM soft-gel capsule for insomnia and outline its 2026 outlook. The large, multi-centre trial—designed to meet regulatory standards in Australia, the US and Europe—is approaching completion of recruitment ahead of an interim analysis and represents the final clinical step before a potential submission to the Australian Therapeutic Goods Administration for registration of the insomnia treatment. With no other successful Phase III CBD insomnia trials in Australia to date and a regulatory framework that permits over-the-counter CBD sales through pharmacies once approved, a positive outcome could give Avecho a first-mover advantage in a sizeable and growing sleep-disorder market, positioning the company to capitalise on rising recognition of sleep health as a national priority and the expanding global sleep-economy and CBD sectors.

The most recent analyst rating on (AU:AVE) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on Avecho Biotechnology Limited stock, see the AU:AVE Stock Forecast page.

Avecho Advances Phase III CBD Insomnia Trial, Raises Capital and Secures US/EU Patent Wins

Avecho Biotechnology reported solid progress in its pivotal Phase III trial of its CBD TPM® soft-gel capsule for insomnia, with 190 of the roughly 210 patients required for the interim analysis already dosed and remaining recruitment continuing into early 2026. The company is targeting completion of this interim analysis in the first half of 2026, positioning the read-out as a key clinical and commercial inflection point that could significantly shape its path to market and value for shareholders. To accelerate its route to commercialisation, Avecho raised $2.5 million in a placement completed in November 2025, funding critical commercial-scale manufacturing, stability and regulatory batch work, and capsule production for the second Phase III cohort, with the goal of enabling a prompt TGA submission and preparing supply for Australia and potential licensed territories. The company also strengthened its intellectual property position after the US and European patent offices allowed patents covering its CBD TPM® soft-gel formulation, extending protection over its oral cannabinoid technology to at least 2040 in two of the world’s largest pharmaceutical markets, and supporting possible non-core opportunities beyond CBD. Avecho ended the December quarter with $4.7 million in cash and continued to invest heavily in R&D, particularly the Phase III insomnia trial and related manufacturing and regulatory activities, while noting that quarterly costs were elevated by timing effects and are not expected to remain at the same level.

The most recent analyst rating on (AU:AVE) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on Avecho Biotechnology Limited stock, see the AU:AVE Stock Forecast page.

Avecho Nears Completion of Recruitment for Phase III CBD Trial

Avecho Biotechnology has announced nearing the completion of recruitment for its pivotal Phase III clinical trial for a CBD-enhanced capsule aimed at treating insomnia, with 190 out of the targeted 210 participants already dosed. The successful outcome of this trial could position Avecho as a leader in the Australian CBD market, particularly since regulatory changes allow over-the-counter CBD sales. This progress represents a critical step towards gaining market approvals and tapping into the rapidly growing sleep aids industry.

Avecho Secures US and European Patent Allowances for CBD Soft-Gel Capsule

Avecho Biotechnology Limited has received patent allowances in the US and Europe for its proprietary CBD soft-gel capsule formulation, which is in Phase III clinical trials for insomnia. These patents, expected to be granted by the end of FY26, will protect the formulation until at least 2040, enhancing Avecho’s intellectual property in major markets. This development strengthens Avecho’s position in cannabinoid formulation technology and supports future regulatory and commercial efforts. The ongoing clinical trial, the largest of its kind, aims to support the registration of the CBD TPM soft-gel capsule for insomnia treatment, potentially allowing Avecho to capitalize on a significant market opportunity in Australia.